致病性桥粒斑蛋白基因变异携带者的临床特征与结局
多变量分析显示女性、既往非持续或持续室速、LVEF≤50%与室性心律失常相关,3个以上导联T波倒置和LVEF≤50%与心衰相关,心肌损伤事件与后续室速和心衰风险增加相关。
要点
- DSP变异携带者持续室速年发生率3.9%,心衰住院年发生率1.8%。
- LVEF≤50%同时预测持续室速和心衰住院风险。
- 3个以上导联T波倒置与心衰住院风险相关。
核心结论
- 致病/可能致病性DSP变异携带者持续室速和心衰住院发生率高,具有独特临床表型。
- 既往非持续或持续室速、3个以上导联T波倒置、LVEF≤50%及心肌损伤事件是主要不良结局风险特征。
研究设计与样本
- 全球DSP-ERADOS网络26家学术机构、9个国家的多中心队列研究。
- 主要结局为随访期间持续室性心律失常和心衰住院,采用Fine-Gray回归分析关联因素。
主要发现
- 随访3.7[1.4-7.1]年,139例(17.4%,3.9%/年)发生持续室速,72例(9.0%,1.8%/年)发生心衰住院。
- 32.5%个体不符合ARVC、DCM或NDLVC诊断标准,其室速年发生率为0.5%。
临床怎么用
- 对DSP变异携带者应评估既往室速发作、LVEF和心电图T波倒置导联数。
- LVEF≤50%和3个以上导联T波倒置提示心衰住院风险较高。
- 心肌损伤事件发生后需警惕后续室速和心衰风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory, and structural characteristics. However, cohort sizes have limited full clinical characterization and identification of clinical and demographic predictors of sustained ventricular arrhythmias (VAs), heart failure (HF) hospitalizations, and transplant/death. In particular, the relevance of acute myocarditis-like episodes for subsequent disease course is largely unknown. METHODS: All patients with pathogenic/likely pathogenic (P/LP) DSP variants in the worldwide DSP-ERADOS Network (26 academic institutions across nine countries) were included. The primary outcomes were the development of sustained VA and HF hospitalizations during follow-up. Fine-Gray regressions were used to test association between clinical and instrumental parameters and the development of outcomes. RESULTS: Eight hundred patients [40.3 ± 17.5 years, 47.5% probands, left ventricular ejection fraction (LVEF) 49.5 ± 13.9%] were included. Over 3.7 [1.4-7.1] years, 139 (17.4%, 3.9%/year) and 72 (9.0%, 1.8%/year) patients experienced sustained VA and HF episodes, respectively. A total of 32.5% of individuals did not fulfil diagnostic criteria for ARVC, DCM, or NDLVC; their VA incidence was 0.5%/year. In multivariable regression, risk features associated with the development of VA were female sex [adjusted hazard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009), prior sustained VA (aHR 1.923; P = .006), and LVEF ≤ 50% (aHR: 1.645; P = .032), while for HF, they were the presence of T-wave inversion in 3+ electrocardiogram leads (aHR 2.036, P = .007) and LVEF ≤ 50% (aHR 3.879; P < .001). Additionally, 70 (8.8%) patients experienced a myocardial injury episode at presentation or during follow-up. These episodes were associated with an increased risk of VA and HF thereafter (HR 2.394; P < .001, and HR 5.064, P < .001, respectively). CONCLUSIONS: Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.
引用
- Gasperetti A, Carrick RT, Protonotarios A, et al. Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Eur Heart J. 2025. PMID: 39288222. doi:10.1093/eurheartj/ehae571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。